Imaging of Liver Tumors in Patients with Chronic Liver Disease

详细信息    查看全文

• 作者：Elisabetta Sagrini (1)
  Matteo Renzulli (2)
  Anna Pecorelli (1)
  Federico Stefanini (1)
  Fabio Piscaglia (1)
  
• 关键词：Hepatocellular carcinoma (HCC) ; Intrahepatic cholangiocarcinoma (ICC) ; Contrast ; enhanced ultrasonography (CEUS) ; Focal liver lesions ; Cirrhosis ; HCC noninvasive diagnosis
• 刊名：Current Radiology Reports
• 出版年：2014
• 出版时间：July 2014
• 年：2014
• 卷：2
• 期：7
• 全文大小：
• 参考文献：1. ?-Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2. / Updated American Association of Liver Diseases (AASLD) guidelines on the management of hepatocellular carcinoma.
  2. Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut. 2010;59:638-4. CrossRef
  3. Leoni S, Piscaglia F, Granito A, et al. Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted? Ultraschall Med. 2013;34:280-. CrossRef
  4. -Seitz K, Greis C, Schuler A, et al. Frequency of tumor entities among liver tumors of unclear etiology initially detected by sonography in the noncirrhotic or cirrhotic livers of 1349 patients. Results of the DEGUM multicenter study. Ultraschall Med 2011;32:598-03. / The study collects a huge number of focal liver lesions from one of the largest multicentric studies on ultrasound and contrast- / enhanced ultrasound in cirrhotic and noncirrhotic patients.
  5. ?-Bolondi L, Cillo U, Colombo M, et al. Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig Liver Dis 2013;45:712-3. / Recently released Italian position paper on the management of hepatocellular carcinoma.
  6. ?-EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-3. / Updated European (EASL) guidelines on the management of hepatocellular carcinoma.
  7. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology. 2009;49:658-4. CrossRef
  8. -Matsui O. Detection and characterization of hepatocellular carcinoma by imaging. Clin Gastroenterol Hepatol 2005;3:S136-0. / Review collecting mainstay results about sequential changes of imaging findings according to the progression from precancerous nodules to overt HCC.
  9. Leoni S, Piscaglia F, Golfieri R, et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol. 2010;105:599-09. CrossRef
  10. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-5. CrossRef
  11. Vilana R, Forner A, Bianchi L, et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology. 2010;51:2020-. CrossRef
  12. Khalili K, Kim TK, Jang HJ, et al. Optimization of imaging diagnosis of 1-?cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol. 2011;54:723-. CrossRef
  13. Furlan A, Marin D, Cabassa P, et al. Enhancement pattern of small hepatocellular carcinoma (HCC) at contrast-enhanced US (CEUS), MDCT, and MRI: intermodality agreement and comparison of diagnostic sensitivity between 2005 and 2010 American Association for the Study of Liver Diseases (AASLD) guidelines. Eur J Radiol. 2012;81:2099-05. CrossRef
  14. Quaia E, De Paoli L, Angileri R, et al. Evidence of diagnostic enhancement pattern in hepatocellular carcinoma nodules ??cm according to the AASLD/EASL revised criteria. Abdom Imaging. 2013;38:1245-3. CrossRef
  15. ?-Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-4. / Updated Asian (APASL) guidelines on the management of hepatocellular carcinoma.
  16. ?-Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339-4. / Updated Japanese guidelines on the management of hepatocellular carcinoma.
  17. ?-Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver–update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med 2013;34:11-9. / Updated World- / European Societies of Ultrasound (WFUMB- / EFSUMB) recommendations for CEUS in the liver.
  18. Xu HX, Liu GJ, Lu MD, et al. Characterization of small focal liver lesions using real-time contrast-enhanced sonography: diagnostic performance analysis in 200 patients. J Ultrasound Med. 2006;25:349-1.
  19. Iavarone M, Sangiovanni A, Forzenigo LV, et al. Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell differentiation. Hepatology. 2010;52:1723-0. CrossRef
  20. Boozari B, Soudah B, Rifai K, et al. Grading of hypervascular hepatocellular carcinoma using late phase of contrast enhanced sonography: a prospective study. Dig Liver Dis. 2011;43:484-0. CrossRef
  21. Jang HJ, Kim TK, Burns PN, Wilson SR. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation. Radiology. 2007;244:898-06. CrossRef
  22. Jang HJ, Kim TK, Wilson SR. Small nodules (1-?cm) in liver cirrhosis: characterization with contrast-enhanced ultrasound. Eur J Radiol. 2009;72:418-4. CrossRef
  23. Iavarone M, Piscaglia F, Vavassori S, et al. Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. J Hepatol. 2013;58:1188-3. CrossRef
  24. Yang YL, Yang RJ, Liu X, et al. Correlations between the time–intensity parameters of contrast-enhanced ultrasound and clinical prognosis of hepatocellular carcinoma. Clin Imaging. 2013;37:308-2. CrossRef
  25. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-6. CrossRef
  26. Barreiros AP, Piscaglia F, Dietrich CF. Contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma (HCC): comments on AASLD guidelines. J Hepatol. 2012;57:930-. CrossRef
  27. -Chen LD, Xu HX, Xie XY, et al. Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound. Eur Radiol 2010;20:743-3. / Study utilizing time intensity curve (TIC) analysis, which can improve the diagnostic accuracy of CEUS especially in the characterization and differential diagnosis of HCC versus ICC.
  28. Galassi M, Iavarone M, Rossi S, et al. Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver Int. 2013;33:771-. CrossRef
  29. Burrel M, Llovet JM, Ayuso C, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology. 2003;38:1034-2. CrossRef
  30. Snowberger N, Chinnakotla S, Lepe RM, et al. Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. Aliment Pharmacol Ther. 2007;26:1187-4. CrossRef
  31. Haradome H, Grazioli L, Tinti R, et al. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging. 2011;34:69-8. CrossRef
  32. Choi SH, Lee JM, Yu NC, et al. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI. AJR Am J Roentgenol. 2008;191:529-6. CrossRef
  33. Fidler J, Hough D. Hepatocyte-specific magnetic resonance imaging contrast agents. Hepatology. 2011;53:678-2. CrossRef
  34. ?-Kudo M, Matsui O, Sakamoto M, et al. Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the management of hepatocellular carcinoma: consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan. Oncology 2013;84 Suppl 1:21-. / Updated Japanese proposal for a new, simplified diagnostic flow chart for the diagnosis of hepatocellular carcinoma, highlighting the role of Gd- / EOB- / DTPA MRI.
  35. Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol. 2011;45:133-1. CrossRef
  36. Park G, Kim YK, Kim CS, Yu HC, Hwang SB. Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. Br J Radiol. 2010;83:1010-. CrossRef
  37. Kim YK, Kim CS, Han YM, et al. Comparison of gadoxetic acid-enhanced MRI and superparamagnetic iron oxide-enhanced MRI for the detection of hepatocellular carcinoma. Clin Radiol. 2010;65:358-5. CrossRef
  38. Sano K, Ichikawa T, Motosugi U, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology. 2011;261:834-4. CrossRef
  39. Golfieri R, Renzulli M, Lucidi V, et al. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (??cm) HCC in cirrhosis. Eur Radiol. 2011;21:1233-2. CrossRef
  40. Marin D, Di Martino M, Guerrisi A, et al. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT. Radiology. 2009;251:85-5. CrossRef
  41. Ahn SS, Kim MJ, Lim JS, et al. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology. 2010;255:459-6. CrossRef
  42. Choi YS, Rhee H, Choi JY, et al. Histological characteristics of small hepatocellular carcinomas showing atypical enhancement patterns on gadoxetic acid-enhanced MR imaging. J Magn Reson Imaging. 2013;37:1384-1. CrossRef
  43. Kogita S, Imai Y, Okada M, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol. 2010;20:2405-3. CrossRef
  44. Kumada T, Toyoda H, Tada T, et al. Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol. 2011;197:58-3. CrossRef
  45. Higaki A, Ito K, Tamada T, et al. High-risk nodules detected in the hepatobiliary phase of Gd-EOB-DTPA-enhanced MR imaging in cirrhosis or chronic hepatitis: incidence and predictive factors for hypervascular transformation, preliminary results. J Magn Reson Imaging. 2013;37:1377-3. CrossRef
  46. Hyodo T, Murakami T, Imai Y, et al. Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. Radiology. 2013;266:480-0. CrossRef
  47. Choi JW, Lee JM, Kim SJ, et al. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology. 2013;267:776-6. CrossRef
  48. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology. 2010;254:47-6. CrossRef
  49. Takayama T, Makuuchi M, Hirohashi S, et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet. 1990;336:1150-. CrossRef
  50. Park MJ, Kim YK, Lee MH, Lee JH. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (?.0?cm) in patients with hepatitis-induced liver cirrhosis. Acta Radiol. 2013;54:127-6. CrossRef
  51. von Herbay A, Vogt C, Willers R, Haussinger D. Real-time imaging with the sonographic contrast agent SonoVue: differentiation between benign and malignant hepatic lesions. J Ultrasound Med. 2004;23:1557-8.
  52. Quaia E, Calliada F, Bertolotto M, et al. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology. 2004;232:420-0. CrossRef
  53. Nicolau C, Bru C. Focal liver lesions: evaluation with contrast-enhanced ultrasonography. Abdom Imaging. 2004;29:348-9. CrossRef
  54. Kim SJ, Lee JM, Han JK, et al. Peripheral mass-forming cholangiocarcinoma in cirrhotic liver. AJR Am J Roentgenol. 2007;189:1428-4. CrossRef
  55. Chen LD, Xu HX, Xie XY, et al. Enhancement patterns of intrahepatic cholangiocarcinoma: comparison between contrast-enhanced ultrasound and contrast-enhanced CT. Br J Radiol. 2008;81:881-. CrossRef
  56. Rimola J, Forner A, Reig M, et al. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology. 2009;50:791-. CrossRef
  57. Kim SA, Lee JM, Lee KB, et al. Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern–correlation with clinicopathologic findings. Radiology. 2011;260:148-7. CrossRef
  58. Bohle W, Clemens PU, Heubach T, Zoller WG. Contrast-enhanced ultrasound (CEUS) for differentiating between hepatocellular and cholangiocellular carcinoma. Ultraschall Med. 2012;33:E191-. CrossRef
  59. -Li R, Zhang X, Ma KS, et al. Dynamic enhancing vascular pattern of intrahepatic peripheral cholangiocarcinoma on contrast-enhanced ultrasound: the influence of chronic hepatitis and cirrhosis. Abdom Imaging 2013;38:112-. / First study that compared the CEUS appearance of ICC on cirrhotic versus noncirrhotic livers.
  60. -Dietrich CF, Averkiou MA, Correas JM, et al. An EFSUMB introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion. Ultraschall Med 2012;33:344-1. / The article reviews the recommendation and methodology for quantification of ultrasound images, technical aspects and result interpretation.
  61. Quaia E, Palumbo A, Rossi S, et al. Comparison of visual and quantitative analysis for characterization of insonated liver tumors after microbubble contrast injection. AJR Am J Roentgenol. 2006;186:1560-0. CrossRef
  62. Pei XQ, Liu LZ, Liu M, et al. Contrast-enhanced ultrasonography of hepatocellular carcinoma: correlation between quantitative parameters and histological grading. Br J Radiol. 2012;85:e740-. CrossRef
  63. D’Onofrio M, Vecchiato F, Cantisani V, et al. Intrahepatic peripheral cholangiocarcinoma (IPCC): comparison between perfusion ultrasound and CT imaging. Radiol Med. 2008;113:76-6. CrossRef
  64. Soyer P, Bluemke DA, Sibert A, Laissy JP. MR imaging of intrahepatic cholangiocarcinoma. Abdom Imaging. 1995;20:126-0. CrossRef
  65. Chung YE, Kim MJ, Park YN, et al. Varying appearances of cholangiocarcinoma: radiologic–pathologic correlation. Radiographics. 2009;29:683-00. CrossRef
  66. -Kim SH, Lee CH, Kim BH, et al. Typical and atypical imaging findings of intrahepatic cholangiocarcinoma using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr 2012;36:704-. / The study correlates the MRI appearance of ICCs according to histopathology and highlights the concept of the “cloud-sign in the hepatobiliary phase, which seems to be characteristic of ICC.
  67. -Xu J, Igarashi S, Sasaki M, et al. Intrahepatic cholangiocarcinomas in cirrhosis are hypervascular in comparison with those in normal livers. Liver Int 2012;32:1156-4. / One of the first studies describing the hypervascular appearance of ICC on cirrhosis versus noncirrhotic livers and correlating it to the histopathology of the different tumors.
  68. Seymour K, Charnley RM. Evidence that metastasis is less common in cirrhotic than normal liver: a systematic review of post-mortem case–control studies. Br J Surg. 1999;86:1237-2. CrossRef
  69. Strobel D, Seitz K, Blank W, et al. Contrast-enhanced ultrasound for the characterization of focal liver lesions–diagnostic accuracy in clinical practice (DEGUM multicenter trial). Ultraschall Med. 2008;29:499-05. CrossRef
  70. Caturelli E, Bartolucci F, Biasini E, et al. Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. Am J Gastroenterol. 2002;97:397-05. CrossRef
  71. Foschi FG, Dall’Aglio AC, Marano G, et al. Role of contrast-enhanced ultrasonography in primary hepatic lymphoma. J Ultrasound Med. 2010;29:1353-.
  
• 作者单位：Elisabetta Sagrini (1)
  Matteo Renzulli (2)
  Anna Pecorelli (1)
  Federico Stefanini (1)
  Fabio Piscaglia (1)
  
  1. Division of Internal Medicine, Department of Medical and Surgical Sciences, General and University Hospital S. Orsola-Malpighi, Via Albertoni 15, 40138, Bologna, Italy
  2. Division of Radiology, Department of Digestive Diseases and Internal Medicine, General and University Hospital S. Orsola-Malpighi, Via Albertoni 15, 40138, Bologna, Italy
  
• ISSN：2167-4825

文摘

Imaging techniques have become the accepted mainstay for the assessment of liver lesions in cirrhosis and, thanks to the improvement of their diagnostic capabilities in recent years, have further limited the need to resort to bioptic sampling. Hepatocellular carcinoma (HCC) is the most common cause of de-novo liver nodules in cirrhosis, and its diagnosis relies on noninvasive contrast-enhanced imaging studies. Diagnostic criteria have been extensively validated, and the vascular pattern deemed typical for HCC is an arterial hyperenhancement of the nodule followed by washout in the portal or late phase. This pattern provides a positive predictive value for the diagnosis of HCC of about 97?% in nodules in cirrhosis according to the literature. However, the need for a more precise differentiation from other malignancies arising in cirrhosis, making up the remaining about 3?%, and specifically intrahepatic cholangiocarcinoma, has over time led to changes in the recommendations for the noninvasive diagnosis of HCC in cirrhosis. The present review aims to report recently published interesting studies that have brought new insights into the problem of the characterization and differential diagnosis of liver tumors in chronic liver diseases.